2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD.
Daily Equity Report INDIAN MARKET
INDIAN FACE
INDIAN EQUITY BENCHMARK closed marginally higher amid volatility led by buying among defensive sectors like pharma and IT shares. However, selling pressure in select metal, auto and bank shares capped the upside gains. The broader markets underperformed the benchmark indices- BSE Mid- cap and Small-cap ended marginally negative.
Further, Indiabulls Securities jumped 9.20%, after the company said its wholly owned subsidiary, Indiabulls Distribution Services, acquired 100% of the share capital of India Land and Properties.
Cipla rose 3.23%, after the company's subsidiary company Cipla Europe NV signed a distribution agreement with Serum Institute of India.
GLOBAL FACE
Asian shares were steady on as a further weakening of the yen boosted market sentiment, but gains were limited as investors took profits on such recent performers such as SoftBank Corp.
European shares fell with top euro zone shares extending an early dip after weak manufacturing data in the region's top two economies reignited fears over growth prospects.
US stock index futures poised for a lower opening at the Wall Street on Thursday.
INDICES
CLOSE
PREVIOUS
SENSEX
28067.56
28,032.85
NIFTY
8401.90
8,382.30 ASIAN MARKET
INDICES
CLOSE
PREVIOUS
NIKKEI
17,300.86
17,288.75
HANG SENG
23,349.64
23,373.31
KOSPI
1958.04
1,966.87 SECTORIAL INDICES
INDICES
CLOSE
CHANGE (%)
CNX 100
8,379.25
0.25
S&P CNX 500
6,806.30
0.13
CNX MIDCAP
12,254.05
-0.04
CNX 200
4,308.55
0.14
BANK NIFTY
17,645.05
0.34 TOP GAINERS
SCRIPT
CLOSE
CHANGE (%)
KOTAKBNK
1,151.00
6.82
CIPLA
622.50
3.89
TECHM
2,717.40
3.43
SBIN
297.10
2.08 TOP LOSERS
SCRIPT
CLOSE
CHANGE (%)
JINDALSTEL
146.05
-3.91
ZEEL
375.00
-3.49
NMDC
144.85
-3.01
SSLT
234.70
-2.37
3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD.
Daily Equity Report MARKET MOVERS UPSIDE
NIFTY SPOT TREND STRATEGY
BULLISH
BUY ON DIPS PIVOT POINTS
S3
S2
S1
P
R1
R2
R3
8273
8330
8366
8388
8424
8446
8504 NIFTY SUPPORT RESISTANCE
S1-8290
R1-8370
S2-8210
R2-8430 BANK NIFTY FUTURE TREND STRATEGY
BULLISH
BUY ON DIPS PIVOT POINTS
S3
S2
S1
P
R1
R2
R3
17355
17505
17595
17655
17745
17805
17955 BANK NIFTY SUPPORT RESISTANCE
S1-17290
R1-17550
S2-17150
R2-17750
SCRIPT
CLOSE
CHANGE (%)
TCS
2605.45
1.23
ONGC
385.75
0.42
RELIANCE
980.75
0.27
ITC
370.05
0.6 MARKET MOVERS DOWNSIDE
SCRIPT
CLOSE
CHANGE (%)
HDFC BANK
918.20
[0.9]
COAL INDIA
346.75
[0.09]
SBIN
297.10
[89.79]
BHARTI ARTL
397.75
[1] FII & DII ACTIVITY
INSTITUTION
NET BUY (CR.)
NET SELL (CR)
FII
3163.39
3640.54
DII
1271
1169.38 NSE TOTALS
INDICES
ADVANCES
DECLINES
NIFTY
21
29
BANK NIFTY
3
9
4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD.
Daily Equity Report r MARKET TALKS
Rs1593 The stock has hit a high of Rs1635 and a low of Rs1424. Total traded quantity on the counter stood at over 0.25 lakh shares. Earlier there was upsurge in volume on November 7.
ITD Cementation zooms 10% on stake buy
Shares of ITD Cementation India rallied hit 10% upper circuit to Rs460.50 on NSE after the HDFC MF bought 238,000 shares or 1.5% stake in the construction and engineering company via open market. On Nov 19, HDFC M F and HDFC Trustee Co A/c HDFC Infrastructure Fund purchased 119,000 shares each at Rs419 per share, the NSE and BSE bulk deals data shows.
NTPC launches issue of $ 5 Cr Fixed Rate Unsecured Notes
NTPC has launched a issue of $ 5 Cr Fixed Rate Unsecured Notes due 2024 which were priced on Nov 19, 2014. The Notes carry a coupon of 4.375% p.a. payable semi-annually and are of 10 years tenor. The Notes are expected to be settled by Nov 26, 2014.The Notes represent unsecured obligations of the Issuer and will rank pari passu with all its other existing and future unsubordinated obligations.
Ranbaxy Laboratories stock up 3%
Shares of Ranbaxy Laboratories was higher by 3% to Rs 619, on back of heavy volumes.The stock has hit a high of Rs625 and a low of Rs587.The company has filed a complaint against the USFDA in D C federal court and have also asked the court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided.
Dr Reddy's gets approval for Allegra- D
Dr Reddy’s Lab has got USFDA final approval for over the counter version of ant-allergy drug sold under brand name of Allegra-D. The market size of this drug is pegged at US$250mn).The promoter of Shriram EPC has increased its shareholding from 41.33% to 69.87% (bought 3.2cr shares at Rs50 for an aggregate consideration of around Rs160 crore), under the Corporate Debt Restructuring (CDR).
Bajaj Holdings stock zooms 12%
Shares of Bajaj Holdings and Investment Ltd surged 12% at.
The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Use of this report in no way constitutes a client/advisor relationship, all information we communicate to you (the subscriber) either through our Web site or other forms of communications, are purely for informational purposes only. We recommend seeking individual investment advice before making any investment, for you are assuming sole liability for your investments. Capital Stars will in no way have discretionary authority over your trading or investment accounts. All rights reserved.
DISCLAIMER
